Bali Muralidhar, Director at Reneo Pharmaceuticals, Inc. (RPHM), bought 33,210 shares at $9.50 ($315K) on 2021-06-08, disclosed to the SEC on 2021-06-10.
Open-market purchase of $315k RPHM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.50 | 16,605 | $158K | 50.0% |
| 2 | $9.50 | 16,605 | $158K | 50.0% |
| Total | $9.50 avg | 33,210 | $315K | 100% |
| Filing → |
| RPHM | BUY | 2021-06-25 | $384K | — | Filing → |
| RPHM | BUY | 2021-06-23 | $845K | — | Filing → |
| RPHM | BUY | 2021-06-07 | $114K | — | Filing → |